The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for ...

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC ...

Cambridge-based AstraZeneca looks like it has set another drug on its way to blockbuster status - Datroway for the treatment ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been granted accelerated approval by the US Food ...

Daiichi Sankyo and MSD's partnership, which began in October 2023, encompasses the co-development and commercialisation of patritumab deruxtecan (HER3-DXd), raludotatug deruxtecan (R-DXd), and I-DXd.